PRINCETON, N.J.--(BUSINESS WIRE)--ArrePath today announced the appointment of Michael Dudley, PharmD, as Chairman of the Company’s Board of Directors.
“Dr. Dudley has an outstanding record of research, development and business leadership in anti-infectives in both established and emerging companies,” said Lloyd Payne, PhD, ArrePath’s President and CEO. “We look forward to his guidance and insights on our Board as we advance our machine-learning-based platform for the discovery of new and differentiated classes of anti-infectives.”
Dr. Dudley has more than 30 years of experience in anti-infective R&D and commercialization. During his career, Dr. Dudley has overseen R&D and regulatory approval of multiple antibiotic products, including the discovery and development of a new chemical class of beta-lactamase inhibitors, using the element boron, that resulted in the first FDA-approved product in this class. He has also led negotiations for over $200 million in multiple public-private partnerships to advance the research and development of antimicrobial agents worldwide.
“There is a critical need for new classes of antibiotics for drug resistant infections,” said Dr. Dudley. “ArrePath is building an exceptional team and pursuing a highly innovative strategy using modern tools and approaches to antimicrobial drug discovery. I welcome the opportunity to work with the ArrePath team and its Board.”
Dr. Dudley is currently President and CEO of Qpex Biopharma, a clinical stage company he has led since its founding and Series A financing in 2018 as a spin-out from The Medicines Company (MDCO). He had joined MDCO following its acquisition of Rempex in 2013, and he remained as CSO and co-leader of the Infectious Disease Business Unit as it developed and launched 3 antibiotic products. Before Rempex/MDCO, he held leadership positions of increasing responsibility at the biotech companies Mpex, Diversa, and Microcide. Prior to his career in industry, he held academic appointments at the University of Rhode Island College of Pharmacy and Brown University School of Medicine and practiced in patient care and antibiotic stewardship. He has published over 400 scientific papers/book chapters/presentations on the evaluation and clinical use of anti-infectives. He completed undergraduate work at Pepperdine University, his PharmD and residency at the University of California San Francisco (UCSF), and a fellowship in infectious diseases at Hartford Hospital.
About ArrePath
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections. The company’s proprietary machine learning (ML)-based platform enables the rapid and efficient identification of anti-infective agents with new mechanisms of action at the outset of the discovery process, through a deep understanding and analysis of pathogen behavior. The platform’s proof-of-concept has been demonstrated in studies published in Cell by ArrePath’s scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures. Learn more at www.arrepath.com and follow us on Twitter @ArrePath.
